EP Patent

EP0518435A1 — Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use

Assigned to Janssen Pharmaceutica NV · Expires 1992-12-16 · 33y expired

What this patent protects

The present invention is concerned with novel imidazo[2,1-b][3]benzazepines of formula the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; R¹ represents hy…

USPTO Abstract

The present invention is concerned with novel imidazo[2,1-b][3]benzazepines of formula the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; R¹ represents hydrogen, halo, C₁₋₄alkyl or C₁₋₄alkyloxy; R² represents hydrogen, halo, C₁₋₄alkyl or C₁₋₄alkyloxy; R³ represents hydrogen, C₁₋₄alkyl, ethenyl substituted with hydroxycarbonyl or C₁₋₄alkyloxycarbonyl, C₁₋₄alkyl substituted with hydroxycarbonyl or C₁₋₄alkyloxycarbonyl, hydroxyC₁₋₄alkyl, formyl or hydroxycarbonyl; R⁴ represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, phenyl or halo; R⁵ represents hydrogen, C₁₋₄alkyl or halo; L represents hydrogen; C₁₋₆alkyl; C₁₋₆alkyl substituted with one substituent selected from the group consisting of hydroxy, halo, C₁₋₄alkyloxy, hydroxycarbonyl, C₁₋₄alkyloxycarbonyl, C₁₋₄alkyloxycarbonyl-C₁₋₄alkyloxy, hydroxycarbonylC₁₋₄alkyloxy, C₁₋₄alkyloxycarbonylamino, C₁₋₄alkylaminocarbonyl, C₁₋₄alkylaminocarbonylamino, C₁₋₄alkylaminothiocarbonylamino, aryl, aryloxy and arylcarbonyl; C₁₋₆alkyl substituted with both hydroxy and aryloxy; C₃₋₆alkenyl; C₃₋₆alkenyl substituted with aryl; or, L represents a radical of formula -Alk-Y-Het¹ (a-1), -Alk-NH-CO-Het² (a-2) or -Alk-Het³ (a-3); provided that 6,11-dihydro-11-(4-piperidinylidene)-5 H -imidazo[2,1-b][3]benzazepine is ecxluded, which are useful antiallergic compounds. Compositions comprising said compounds, methods of using and processes for preparing the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP0518435A1
Jurisdiction
EP
Classification
Expires
1992-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.